CDK4/6 inhibitors in HR+ breast cancer: three approvals, one class

Three CDK4/6 inhibitors carry FDA approval for hormone-receptor-positive, HER2-negative metastatic breast cancer, and a fourth has joined the adjuvant setting. They all target the same kinase pair, all combine with endocrine therapy, all gate the G1-to-S transition at the retinoblastoma checkpoint. But the three drugs are not interchangeable once you look past the mechanism, and the differences that matter clinically come down to selectivity, dosing schedule, and the off-target profile each chemotype carries with it.

Why CDK4/6 was the pharmacology bet

In HR-positive breast cancer, estrogen receptor signaling drives cyclin D1 transcription. Cyclin D1 partners with CDK4 and CDK6, the complex phosphorylates the retinoblastoma protein (Rb), Rb releases E2F, and the cell commits to S phase. Hit CDK4/6 and you stall that commitment step. The cell does not die, it senesces or arrests. Combine with endocrine therapy that drops the upstream estrogen signal and you get durable cytostasis rather than a quick rebound.

Earlier pan-CDK inhibitors (flavopiridol, dinaciclib) failed in solid tumors because they also took out CDK1, CDK2, and CDK9. Killing CDK1 means killing every dividing cell in the body, which is why those molecules behaved like cytotoxic chemotherapy with kinase-inhibitor pharmacokinetics. The CDK4/6-selective generation, starting with palbociclib, finally captured the cytostatic effect without the bone marrow wipeout.

The three approved compounds

• Palbociclib (PD-0332991, Ibrance) — Pfizer, FDA approved February 2015. PALOMA-2 reported a median progression-free survival of 24.8 months with letrozole versus 14.5 months on letrozole alone in first-line metastatic disease. 125 mg once daily, three weeks on and one week off. The dose-limiting toxicity is neutropenia, which is on-mechanism CDK6 inhibition in the myeloid lineage rather than a cytotoxic effect.
• Ribociclib (LEE011, Kisqali) — Novartis, FDA approved March 2017. MONALEESA-2 showed similar PFS benefit in first-line, and MONALEESA-7 extended the readout into premenopausal patients with ovarian suppression. The signal that changed prescribing was overall survival: MONALEESA-3 and -7 both crossed statistical significance for OS, while palbociclib trials largely did not. Ribociclib also carries a QT prolongation warning that the others do not, traceable to its hERG affinity, so baseline and on-treatment ECGs are required.
• Abemaciclib (LY2835219, Verzenio) — Eli Lilly, FDA approved September 2017. Different scheduling: continuous twice-daily dosing rather than the three-on-one-off cycle. The chemistry is more CDK4-leaning relative to CDK6, which shifts the toxicity profile away from neutropenia and toward diarrhea, the dose-limiting adverse event in MONARCH-2 and MONARCH-3. monarchE made abemaciclib the first CDK4/6 inhibitor approved in the adjuvant setting in 2021 for high-risk early breast cancer, where it produced a durable invasive disease-free survival benefit.

Dalpiciclib (Hengrui, approved in China 2021) and the ribociclib adjuvant indication out of NATALEE (2024) round out the current clinical landscape. NATALEE in particular extended CDK4/6 benefit to a broader stage-II and stage-III population than monarchE captured, with three years of ribociclib on top of endocrine therapy.

Resistance: not one mutation, several mechanisms

Unlike EGFR or ALK, CDK4/6 inhibitor resistance does not converge on a single gatekeeper mutation. The recurring drivers in clinical samples include Rb loss-of-function (the most disabling, since the whole point of CDK4/6 inhibition is to keep Rb hypophosphorylated), cyclin E1 amplification (which bypasses CDK4/6 by activating CDK2 instead), FAT1 loss (de-represses cyclin D1), and reactivation of upstream growth signaling through ESR1, AKT1, or PIK3CA mutations. The clinical implication is that the post-progression combinations usually pivot to a different node — selective ER degraders for ESR1, PI3K-alpha inhibitors for PIK3CA, mTOR inhibitors for general upstream rescue — rather than escalating to a more potent CDK4/6 inhibitor.

Try the docking yourself

The canonical CDK6 ATP-pocket structure with palbociclib is 2EUF, and the abemaciclib-bound CDK6 structure is 5L2S. Open Studio and pick CDK6 from the target catalog to dock candidates against the same ATP pocket the three approved drugs occupy. The hinge contact is to Val101, the gatekeeper is Phe98. Liganx is a free molecular docking online tool, and the ADMET panel will flag hERG liability — useful if you want to see why ribociclib carries the QT label and palbociclib does not. Molecular docking against CDK6 with the ADMET readout is exactly the workflow this class motivates.

Primary sources

• Finn RS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. NEJM 375, 1925-1936 (2016). doi:10.1056/NEJMoa1607303
• Hortobagyi GN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. NEJM 375, 1738-1748 (2016). doi:10.1056/NEJMoa1609709
• Goetz MP, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35, 3638-3646 (2017). doi:10.1200/JCO.2017.75.6155
• Slamon DJ, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. NEJM 390, 1080-1091 (2024). doi:10.1056/NEJMoa2305488